Upregulation	B:C0949479
and	O
activation	B:C1514758
of	O
δ	O
‑opioid	B:C0140057
receptors	I:C0140057
p	I:C0140057
romotes	O
the	O
progression	B:C1947901
of	O
human	B:C0086418
b	O
reast	B:C0006142
cancer	I:C0006142
.	O

δ‑opioid	B:C0140057
receptor	I:C0140057
(	O
DOR	B:C0140057
)	O
belongs	O
to	O
the	O
family	O
of	O
G	O
protein	B:C0682972
‑coupled	I:C0682972
receptors	I:C0682972
(	O
G	B:C0682972
protein	I:C0682972
‑coupled	I:C0682972
receptors	I:C0682972
)	O
.	O

Numerous	O
studies	O
have	O
shown	O
that	O
DOR	B:C0140057
is	O
widely	O
distributed	O
in	O
human	B:C0086418
peripheral	B:C0040300
tissues	I:C0040300
and	O
is	O
closely	O
related	O
to	O
the	O
development	B:C0243107
and	O
progression	B:C1947901
of	O
certain	O
malignant	B:C0006826
tumours	I:C0006826
.	O

However	O
,	O
there	O
is	O
controversy	O
in	O
the	O
literature	O
regarding	O
whether	O
DOR	B:C0140057
has	O
an	O
impact	O
on	O
the	O
development	B:C0243107
and	O
progression	B:C1947901
of	O
human	B:C0086418
breast	B:C0006142
cancer	I:C0006142
.	O

The	O
present	O
study	B:C2603343
comprehensively	O
elaborates	O
on	O
the	O
biological	B:C3714634
functions	I:C3714634
of	O
DOR	B:C0140057
by	O
determining	O
the	O
distribution	O
of	O
DOR	B:C0140057
expression	O
in	O
breast	B:C0006142
cancer	I:C0006142
tissues	B:C0040300
and	O
cells	B:C0334227
and	O
by	O
further	O
verifying	O
the	O
effects	O
of	O
DOR	B:C0140057
on	O
breast	B:C0006142
cancer	I:C0006142
progression	B:C1947901
.	O

DOR	B:C0140057
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
human	B:C0086418
breast	B:C0006142
cancer	I:C0006142
tissues	B:C0040300
and	O
cells	B:C0334227
.	O

In	O
addition	O
,	O
the	O
high	O
expression	O
level	O
of	O
DOR	B:C0140057
positively	B:C1514241
correlated	O
with	O
tumour	O
grade	O
and	O
clinical	B:C1300072
stage	I:C1300072
and	O
negatively	B:C1513916
correlated	O
with	O
breast	B:C0006142
cancer	I:C0006142
metastasis	B:C4255448
and	O
prognosis	B:C1516221
.	O

Upregulating	B:C0949479
and	O
activating	B:C1514758
DOR	B:C0140057
promoted	O
the	O
proliferation	B:C0596290
of	O
human	B:C0086418
breast	B:C0006142
cancer	I:C0006142
cells	B:C0334227
in	O
a	O
concentration	O
‑dependent	O
manner	O
within	O
a	O
specific	O
concentration	O
range	O
,	O
whereas	O
downregulating	B:C0013081
or	O
inhibiting	O
DOR	B:C0140057
activation	B:C1514758
significantly	O
suppressed	O
cell	B:C0596290
proliferation	I:C0596290
.	O

The	O
majority	O
of	O
tumour	B:C0334227
cells	I:C0334227
were	O
arrested	B:C1155873
in	O
G1	O
phase	O
,	O
and	O
some	O
cells	B:C0334227
exhibited	O
apoptosis	B:C0162638
.	O

DOR	B:C0140057
upregulation	B:C0949479
and	O
activation	B:C1514758
induced	O
protein	B:C1259877
kinase	I:C1259877
C	I:C1259877
(	O
protein	B:C1259877
kinase	I:C1259877
C	I:C1259877
)	O
activation	O
,	O
resulting	O
in	O
increased	O
phosphorylation	B:C0031715
levels	O
of	O
extracellular	B:C0600388
signal	I:C0600388
‑regulated	I:C0600388
kinases	I:C0600388
(	O
extracellular	B:C0600388
signal	I:C0600388
‑regulated	I:C0600388
kinases	I:C0600388
)	O
.	O

After	O
inhibition	O
of	O
the	O
P	B:C1259877
KC	I:C1259877
/	O
ERK	O
signalling	O
pathway	O
,	O
the	O
effects	O
of	O
DOR	B:C0140057
on	O
breast	B:C0006142
cancer	I:C0006142
were	O
significantly	O
attenuated	O
in	B:C1515655
vivo	I:C1515655
and	O
in	O
vitro	O
.	O

In	O
summary	B:C0242482
,	O
DOR	B:C0140057
is	O
highly	O
expressed	O
in	O
breast	B:C0006142
cancer	I:C0006142
and	O
is	O
closely	O
related	O
to	O
its	O
progression	B:C1947901
.	O

These	O
results	O
suggest	O
that	O
DOR	B:C0140057
may	O
serve	O
as	O
a	O
potential	O
biomarker	B:C0005516
for	O
the	O
early	O
diagnosis	B:C0011900
of	O
breast	B:C0006142
cancer	I:C0006142
and	O
may	O
be	O
a	O
viable	O
molecular	B:C1513403
target	I:C1513403
for	O
therapeutic	B:C0808232
intervention	I:C0808232
.	O

